Novel Glaucoma Treatment Using Genome Editing

使用基因组编辑的新型青光眼治疗

基本信息

  • 批准号:
    9254557
  • 负责人:
  • 金额:
    $ 50.84万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-04-01 至 2019-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Primary open angle glaucoma (POAG) is a leading cause of irreversible vision loss and blindness. Current treatments of POAG are aimed at reducing intraocular pressure (IOP), the most important risk factor for the development and progression of the disorder. However, current glaucoma treatments do not address the underlying disease mechanisms. Mutations in the myocilin gene (MYOC) are the most common known genetic cause of glaucoma. Three developments provide us with an opportunity to investigate novel treatments of glaucoma directed at the underlying disease mechanisms: 1. The development of a POAG mouse model (Tg- MYOCY437H) in our laboratory that expresses mutant myocilin encoded by the MYOC gene; 2. The use of the Tg-MYOCY437H mouse model to demonstrate in vivo that mutant myocilin accumulates in the endoplasmic reticulum (ER) and induces ER stress in the trabecular meshwork (TM) of the eye as a key mechanistic component leading to glaucoma; and 3. The recent development of genome editing nucleases as a valuable tool for gene therapy applications. Furthermore, the fact that myocilin-associated POAG results from dominant gain of function mutations and the fact that ER stress induced apoptosis in the TM leads to POAG provide an opportunity to explore novel glaucoma treatments by in vivo elimination of mutant MYOC and/or apoptosis pathway genes (e.g. Chop). We propose to utilize the Tg-MYOCY437H mouse model of glaucoma to further explore the role of ER stress in POAG and to use a novel genome editing method (CRISPR) to explore novel POAG treatments, specifically the elimination of mutant myocilin from the TM of Tg-MYOCY437H mice, as well as the elimination of ER stress genes from TM cells. Clustered regularly interspaced short palindromic repeats (CRISPR) is an endogenous nuclease system, which uses RNA sequences to guide the cleavage of DNA by the CRISPR-associated nuclease Cas9. In addition, we will explore the role of ER stress in steroid induced glaucoma for the purpose of determining whether the genome editing strategy of glaucoma treatment can be applied to this form of glaucoma. Importantly, we will extend our work to humans by exploring the utility of genome editing in a human eye perfusion organ culture system. We believe that Cas9 can be used to remove the mutant MYOC gene and provide the first effective cure for MYOC mutation-induced glaucoma. In addition, the eye is an ideal test site for establishing the therapeutic potential of the Cas9 technology, and this work will pave the path for the application of Cas9 for treating a variety of genetic eye disorders, as well disorders affecting other organ systems.
描述(由申请人提供):原发性开角型青光眼(POAG)是导致不可逆性视力丧失和失明的主要原因。目前POAG的治疗旨在降低眼压,眼压是POAG发生和发展的最重要的危险因素。然而,目前的青光眼治疗方法并没有解决潜在的疾病机制。肌红素基因(MYOC)突变是青光眼最常见的遗传原因。三项进展为我们提供了一个机会来研究针对青光眼潜在疾病机制的新的治疗方法:1.我们实验室建立的POAG小鼠模型(TG-MYOCY437H)表达由MYOC基因编码的突变的myoclin;2.利用TG-MYOCY437H小鼠模型在体内证明突变的myoclin积聚在内质网(ER)并诱导作为导致青光眼的关键机制组件的小梁网(TM)的ER应激;以及3.基因组编辑核酸酶作为基因治疗应用的有价值的工具的最新发展。此外,肌球蛋白相关的POAG是由于功能突变的显性获得,以及内质网应激诱导TM中的细胞凋亡导致POAG的事实,为通过体内消除突变的MYOC和/或凋亡途径基因(如CHOP)来探索新的青光眼治疗方法提供了机会。我们建议利用TG-MYOCY437H小鼠青光眼模型进一步探讨内质网应激在POAG中的作用,并使用一种新的基因组编辑方法(CRISPR)来探索新的POAG治疗方法,特别是从TG-MYOCY437H小鼠的TM中消除突变的myoclin,以及从TM细胞中消除ER应激基因。簇状规则间隔短回文重复序列(CRISPR)是一个内源核酸酶系统,它使用RNA序列来指导CRISPR相关核酸酶Cas9对DNA的切割。此外,我们还将探讨内质网应激在激素性青光眼中的作用,以确定青光眼治疗的基因组编辑策略是否适用于这种形式的青光眼。重要的是,我们将通过探索基因组编辑在人眼灌流器官培养系统中的应用,将我们的工作扩展到人类。我们相信Cas9可以用来去除突变的MYOC基因,为MYOC突变引起的青光眼提供第一个有效的治疗方法。此外,眼睛是确定Cas9技术治疗潜力的理想试验点,这项工作将为Cas9应用于治疗各种遗传性眼部疾病以及影响其他器官系统的疾病铺平道路。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Abbot Frederick Clark其他文献

Abbot Frederick Clark的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Abbot Frederick Clark', 18)}}的其他基金

Glucocorticoids, ocular hypertension and glaucoma
糖皮质激素、高眼压症和青光眼
  • 批准号:
    10468972
  • 财政年份:
    2020
  • 资助金额:
    $ 50.84万
  • 项目类别:
Glucocorticoids, ocular hypertension and glaucoma
糖皮质激素、高眼压症和青光眼
  • 批准号:
    10675041
  • 财政年份:
    2020
  • 资助金额:
    $ 50.84万
  • 项目类别:
Glucocorticoids, ocular hypertension and glaucoma
糖皮质激素、高眼压症和青光眼
  • 批准号:
    10261587
  • 财政年份:
    2020
  • 资助金额:
    $ 50.84万
  • 项目类别:
Glucocorticoids, ocular hypertension and glaucoma
糖皮质激素、高眼压症和青光眼
  • 批准号:
    10056541
  • 财政年份:
    2020
  • 资助金额:
    $ 50.84万
  • 项目类别:
Novel Genome Editing for the Treatment of Glaucoma
用于治疗青光眼的新型基因组编辑
  • 批准号:
    10613463
  • 财政年份:
    2019
  • 资助金额:
    $ 50.84万
  • 项目类别:
Administrative Supplement for Research on Vitamin B3 Dietary Supplements for Eye Disease
维生素B3膳食补充剂治疗眼病研究行政补充
  • 批准号:
    10725441
  • 财政年份:
    2019
  • 资助金额:
    $ 50.84万
  • 项目类别:
Novel Genome Editing for the Treatment of Glaucoma
用于治疗青光眼的新型基因组编辑
  • 批准号:
    9765843
  • 财政年份:
    2019
  • 资助金额:
    $ 50.84万
  • 项目类别:
Novel Genome Editing for the Treatment of Glaucoma
用于治疗青光眼的新型基因组编辑
  • 批准号:
    10393523
  • 财政年份:
    2019
  • 资助金额:
    $ 50.84万
  • 项目类别:
Conditionally immortalized TM cell and RGC lines from Animal Model
来自动物模型的条件永生化 TM 细胞和 RGC 系
  • 批准号:
    8636379
  • 财政年份:
    2014
  • 资助金额:
    $ 50.84万
  • 项目类别:
Novel Glaucoma Treatment Using Genome Editing
使用基因组编辑的新型青光眼治疗
  • 批准号:
    9039605
  • 财政年份:
    2014
  • 资助金额:
    $ 50.84万
  • 项目类别:

相似海外基金

How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.84万
  • 项目类别:
    Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 50.84万
  • 项目类别:
    Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 50.84万
  • 项目类别:
    Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.84万
  • 项目类别:
    Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 50.84万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.84万
  • 项目类别:
    Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 50.84万
  • 项目类别:
    Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 50.84万
  • 项目类别:
    Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
  • 批准号:
    23K00129
  • 财政年份:
    2023
  • 资助金额:
    $ 50.84万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
  • 批准号:
    2883985
  • 财政年份:
    2023
  • 资助金额:
    $ 50.84万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了